Экономические аспекты осложненного остеопороза: стоимость лечения в течение первого года после перелома

О. В. Добровольская, Наталья Владимировна Торопцова, Ольга Михайловна Лесняк
{"title":"Экономические аспекты осложненного остеопороза: стоимость лечения в течение первого года после перелома","authors":"О. В. Добровольская, Наталья Владимировна Торопцова, Ольга Михайловна Лесняк","doi":"10.14412/1996-7012-2016-3-29-34","DOIUrl":null,"url":null,"abstract":"Objective: to estimate the cost of treatment in patients with complicated osteoporosis (OP) in the first year after fracture under the conditions of the Moscow municipal healthcare system. Patients and methods. The investigation enrolled 196 women (mean age, 65.8±9.1 years) who had sustained fractures at five major osteoporotic sites (proximal hip (PH), distal forearm (DF), surgical humeral neck, vertebral column, and medial and/or lateral ankle). A unified questionnaire that included data on inpatient and outpatient treatment, patients' personal costs, and social benefits, as well as tariffs on services of the Moscow City Fund of Obligatory Health Insurance was used to estimate the cost of treatment for complicated OP during one year after fracture. Results . The direct cost of treatment for PH fracture amounted to 101,243 rubles and was significantly higher (p < 0.01) than that for fractures at other sites: DF (22,080 rubles); humeral neck (39,855 rubles), vertebral column (51,167 rubles), and ankle (43,345 rubles). The average cost of treatment in terms of indirect costs of treatment for complicated OP during a year was as high as 61,151 rubles. In the overall cost structure for the disease, hospital costs accounted for 44%; social benefits were 12% and the cost of antiosteoporotic drugs was only 7%, which was associated with the fact that the latter were rarely prescribed by primary healthcare physicians. Conclusion. Costs of treatment in patients with complicated OP in Moscow were estimated in relation to the site of low-energy fracture. The disease was shown to cause considerable economic losses regardless of the site of osteoporotic fracture; however, the cost of antiosteoporotic drugs has an insignificant share in the overall cost structure for treatment. At the same time, secondary prevention of OP requires that combination antiosteoporotic therapy should be performed in all patients who have sustained low-energy fracture.","PeriodicalId":36215,"journal":{"name":"Sovremennaya Revmatologiya","volume":"10 1","pages":"29-34"},"PeriodicalIF":0.0000,"publicationDate":"2016-09-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"6","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Sovremennaya Revmatologiya","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.14412/1996-7012-2016-3-29-34","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 6

Abstract

Objective: to estimate the cost of treatment in patients with complicated osteoporosis (OP) in the first year after fracture under the conditions of the Moscow municipal healthcare system. Patients and methods. The investigation enrolled 196 women (mean age, 65.8±9.1 years) who had sustained fractures at five major osteoporotic sites (proximal hip (PH), distal forearm (DF), surgical humeral neck, vertebral column, and medial and/or lateral ankle). A unified questionnaire that included data on inpatient and outpatient treatment, patients' personal costs, and social benefits, as well as tariffs on services of the Moscow City Fund of Obligatory Health Insurance was used to estimate the cost of treatment for complicated OP during one year after fracture. Results . The direct cost of treatment for PH fracture amounted to 101,243 rubles and was significantly higher (p < 0.01) than that for fractures at other sites: DF (22,080 rubles); humeral neck (39,855 rubles), vertebral column (51,167 rubles), and ankle (43,345 rubles). The average cost of treatment in terms of indirect costs of treatment for complicated OP during a year was as high as 61,151 rubles. In the overall cost structure for the disease, hospital costs accounted for 44%; social benefits were 12% and the cost of antiosteoporotic drugs was only 7%, which was associated with the fact that the latter were rarely prescribed by primary healthcare physicians. Conclusion. Costs of treatment in patients with complicated OP in Moscow were estimated in relation to the site of low-energy fracture. The disease was shown to cause considerable economic losses regardless of the site of osteoporotic fracture; however, the cost of antiosteoporotic drugs has an insignificant share in the overall cost structure for treatment. At the same time, secondary prevention of OP requires that combination antiosteoporotic therapy should be performed in all patients who have sustained low-energy fracture.
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
复杂骨质疏松症的经济方面:骨折后第一年的治疗成本
目的:评估莫斯科市医疗系统条件下骨折后第一年并发骨质疏松症(OP)患者的治疗费用。患者和方法。该研究招募了196名女性(平均年龄65.8±9.1岁),她们在五个主要骨质疏松部位(髋关节近端(PH)、前臂远端(DF)、手术肱骨颈、脊柱、内侧和/或外侧踝关节)持续骨折。一份统一的调查问卷,包括住院和门诊治疗数据、患者个人费用、社会福利以及莫斯科市强制性健康保险基金的服务费用,用于估计骨折后一年内复杂OP的治疗费用。结果。治疗PH骨折的直接费用为101,243卢布,明显高于其他地点的骨折费用(p < 0.01): DF(22,080卢布);肱骨颈(39,855卢布),脊柱(51,167卢布)和脚踝(43,345卢布)。在一年中,以治疗复杂OP的间接费用计算的平均治疗费用高达61,151卢布。在该疾病的总体成本结构中,住院费用占44%;社会福利占12%,而抗骨质疏松药物的成本仅占7%,这与后者很少由初级保健医生开处方有关。结论。在莫斯科,复杂性OP患者的治疗费用与低能骨折的部位有关。无论骨质疏松性骨折发生在哪个部位,该疾病都会造成相当大的经济损失;然而,抗骨质疏松药物的成本在治疗的整体成本结构中所占的份额微不足道。同时,OP的二级预防要求所有持续性低能骨折患者均应联合抗骨质疏松治疗。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Sovremennaya Revmatologiya
Sovremennaya Revmatologiya Medicine-Pharmacology (medical)
CiteScore
0.70
自引率
0.00%
发文量
82
审稿时长
5 weeks
期刊最新文献
Роль витаминов-антиоксидантов в этиологии ревматоидного артрита Влияние тофацитиниба на показатели функции и качества жизни у больных ревматоидным артритом, резистентных к синтетическим и биологическим базисным противовоспалительным препаратам, в реальной клинической практике (результаты многоцентрового наблюдательного исследования) Остеоартрит и возраст. Роль старения в этиологии и патогенезе заболевания Применение тофацитиниба для лечения больных ревматоидным артритом, резистентных к синтетическим и биологическим базисным противовоспалительным препаратам, в реальной клинической практике ( результаты многоцентрового наблюдательного исследования) Экономические аспекты осложненного остеопороза: стоимость лечения в течение первого года после перелома
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1